In our latest HealthDay Now interview, Dr. Anton Porsteinsson, a principal investigator for the Biogen aducanumab trial, and Dr. Ken Lin, a primary care physician, discuss the controversial new Alzheimer's drug and whether it will provide any benefit to patients, despite its highly uncertain efficacy and steep cost.
Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.